Shedding non-core units while loading up on cash, Mallinckrodt bags $250M in CDMO sale

Discussion in 'Pharma/Biotech Companies - In the News' started by cafead, Sep 10, 2019 at 9:52 AM.

  1. #1 cafead, Sep 10, 2019 at 9:52 AM
    cafead

    cafead Administrator
    Staff Member

    Joined:
    Nov 21, 2001
    Messages:
    32,990
    Likes Received:
    3
    via Mallinckrodt may not be spinning off its specialty generics business any time soon, but the UK drugmaker is seizing every chance to shed subsidiaries that don’t belong in the branded drug company it’s keen to consolidate into.

    In a $250 million deal, Mallinckrodt is selling BioVectra, a contract development and manufacturing organization in Canada, to the private equity firm HIG Capital.

    article source
     
    Quote

Reply to Thread